Table S1.
Univariate analysis of the associations between pelvic bone dose metrics, clinical parameters, and hematological toxicity. OR is calculated when p-value <0.05
| Clinical or pelvic bone DM parameter | Threshold | p-value | OR | |
|---|---|---|---|---|
| Leukopenia G3+ | IMRT vs 3DRT | – | 0.01 | 3.5 |
| Iliac crests V5 | V5>97% | 0.01 | 3.4 | |
| Iliac crests V15 | V15>95% | 0.01 | 3.2 | |
| Lower pelvis V5 | V5>88% | 0.02 | 4 | |
| Lower pelvis V15 | V15>65% | 0.01 | 8.8 | |
| Lower pelvis V20 | V20>50% | 0.01 | 2.8 | |
| TPB V10 | V10>95% | 0.02 | 2.7 | |
| TPB V20 | V20>70% | 0.01 | 2.7 | |
| Nb of chemotherapy cycles | <5 or 5 | 0.60 | – | |
| LA radiation | Yes/no | 0.09 | – | |
| Cisplatin/carboplatin | – | 0.90 | – | |
| WHO performance status | >1 | 0.29 | – | |
| Age | >65 | 0.34 | – | |
| BMI | >25 | 0.9 | – | |
| FIGO | <IIb, IIb, >IIb | 0.92 | – | |
| Leukopenia G4 | IMRT vs 3DRT | – | 0.01 | 191 |
| Iliac crests V15 | V15>95% | 0.02 | 11.9 | |
| Iliac crests V20 | V20>70% | 0.02 | 1.1 | |
| Lower pelvis V5 | V5>95% | 0.01 | 1.1 | |
| Lower pelvis V20 | V20>48% | 0.01 | 1.1 | |
| TPB V10 | V10>90% | 0.03 | 7.9 | |
| TPB V20 | V20>70% | 0.01 | 1.1 | |
| Nb of chemotherapy cycles | <5 or 5 | 0.89 | – | |
| LA radiation | Yes/no | 0.29 | – | |
| Cisplatin/Carboplatin | – | 0.54 | – | |
| WHO performance status | >1 | 0.87 | – | |
| Age | >65 | 0.62 | – | |
| BMI | >25 | 0.19 | – | |
| FIGO | <IIb, IIb, >IIb | 0.28 | – | |
| Neutropenia G3+ | IMRT vs 3DRT | – | 0.17 | – |
| Lower pelvis V10 | V10>75% | 0.01 | 8.7 | |
| Lower pelvis V20 | V20>42% | 0.04 | 3.2 | |
| Nb of chemotherapy cycles | <5 or 5 | 0.31 | – | |
| LA radiation | Yes/no | 0.26 | – | |
| Cisplatin/carboplatin | – | 0.41 | – | |
| WHO performance status | >1 | 0.50 | – | |
| Age | >65 | 0.10 | – | |
| BMI | >25 | 0.67 | – | |
| FIGO | <IIb, IIb, >IIb | 0.26 | – | |
| HT G3+ | IMRT vs 3DRT | – | 0.67 | – |
| Lumbosacral bone V40 | V40>60% | 0.01 | 6.4 | |
| Lumbosacral bone V30 | V30>90% | 0.01 | 5.5 | |
| Nb of chemotherapy cycles | <5 or 5 | 0.65 | – | |
| LA radiation | Yes/no | 0.09 | – | |
| Cisplatin/carboplatin | – | 0.30 | – | |
| WHO performance status | >1 | 0.58 | – | |
| Age | >65 | 0.69 | – | |
| BMI | >25 | 0.22 | – | |
| FIGO | <IIb, IIb, >IIb | 0.32 | – | |
| HT G4 | IMRT vs 3DRT | – | 0.61 | – |
| Iliac crests V20 | V20>60% | 0.01 | 94 | |
| Iliac crests V30 | V30>40% | 0.02 | 82 | |
| Iliac crests Dm | Dm >31 Gy | 0.01 | 4.6 | |
| Lumbosacral bone Dm | Dm >43 Gy | 0.02 | 3.4 | |
| Lower pelvis V5 | V5>95% | 0.01 | 4.6 | |
| Lower pelvis V20 | V20>45% | 0.01 | 4.1 | |
| TPB V5 | V5>95% | 0.02 | 4 | |
| TPB V10 | V10>90% | 0.02 | 3.4 | |
| TPB V20 | V20>65% | 0.01 | 6.5 | |
| IC-TPB V5 | V5>98% | 0.01 | – | |
| Nb of chemotherapy cycles | <5 or 5 | 0.58 | – | |
| LA radiation | Yes/no | 0.17 | – | |
| Cisplatin/carboplatin | – | 0.49 | – | |
| WHO performance status | >1 | 0.36 | – | |
| Age | >65 | 0.84 | – | |
| BMI | >25 | 0.15 | – | |
| FIGO | < IIb | 0.03 | NA | |
| IIb | 3.9 | |||
| > IIb | 99 |
Abbreviations: DM, dose metrics; Nb, number; LA, lumboaortic; TPB, total pelvic bone; IC-TPB, intracavitary total pelvic bone; OR, odds ratio; Dm, mean dose; V, volume; FIGO, International Federation of Gynecology and Obstetrics; BMI, body mass index; WHO, World Health Organization; HT, hematological toxicity.